1. Home
  2. MIRM vs TROX Comparison

MIRM vs TROX Comparison

Compare MIRM & TROX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • TROX
  • Stock Information
  • Founded
  • MIRM 2018
  • TROX N/A
  • Country
  • MIRM United States
  • TROX United States
  • Employees
  • MIRM N/A
  • TROX N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • TROX Major Chemicals
  • Sector
  • MIRM Health Care
  • TROX Industrials
  • Exchange
  • MIRM Nasdaq
  • TROX Nasdaq
  • Market Cap
  • MIRM 1.9B
  • TROX 1.7B
  • IPO Year
  • MIRM 2019
  • TROX 2005
  • Fundamental
  • Price
  • MIRM $44.50
  • TROX $11.00
  • Analyst Decision
  • MIRM Strong Buy
  • TROX Strong Buy
  • Analyst Count
  • MIRM 13
  • TROX 5
  • Target Price
  • MIRM $57.00
  • TROX $18.00
  • AVG Volume (30 Days)
  • MIRM 340.6K
  • TROX 1.2M
  • Earning Date
  • MIRM 11-12-2024
  • TROX 10-24-2024
  • Dividend Yield
  • MIRM N/A
  • TROX 4.55%
  • EPS Growth
  • MIRM N/A
  • TROX N/A
  • EPS
  • MIRM N/A
  • TROX 0.27
  • Revenue
  • MIRM $307,028,000.00
  • TROX $3,084,000,000.00
  • Revenue This Year
  • MIRM $73.07
  • TROX $11.09
  • Revenue Next Year
  • MIRM $27.98
  • TROX $3.44
  • P/E Ratio
  • MIRM N/A
  • TROX $40.97
  • Revenue Growth
  • MIRM 112.14
  • TROX 9.63
  • 52 Week Low
  • MIRM $23.14
  • TROX $10.69
  • 52 Week High
  • MIRM $48.89
  • TROX $20.70
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 65.32
  • TROX 30.75
  • Support Level
  • MIRM $41.09
  • TROX $10.69
  • Resistance Level
  • MIRM $48.89
  • TROX $13.14
  • Average True Range (ATR)
  • MIRM 2.16
  • TROX 0.39
  • MACD
  • MIRM 0.57
  • TROX -0.13
  • Stochastic Oscillator
  • MIRM 59.09
  • TROX 13.06

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About TROX Tronox Holdings plc (UK)

Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. North America, Asia-Pacific and Europe the Middle East, and Africa regions contribute the vast majority of revenue.

Share on Social Networks: